Browse by author
Lookup NU author(s): Professor Moein MoghimiORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2014 Elsevier Inc.Contrary to high expectations, the majority of clinically approved anti-cancer nanomedicine, and those under clinical trials, have shown limited therapeutic efficacy in humans. So, why these nanomedicine are not delivering their promise? Here, we discuss likely factors, and call for a paradigm shift in approach and design of future cancer nanotherapeutics based on realistic cancer models representing human disease, and better understanding of integrated pathophysiological processes, including systems immunology, that modulate human tumor functionality and growth. From the Clinical Editor: This critical review of the current state of translational oncology research utilizing nanomedicine-based approaches provides a comprehensive discussion of the multiple factors that are responsible for poor outcomes when translating these approaches models to the actual human disease.
Author(s): Moghimi SM, Farhangrazi ZS
Publication type: Article
Publication status: Published
Journal: Nanomedicine: Nanotechnology, Biology, and Medicine
Print publication date: 01/11/2014
Online publication date: 14/05/2014
Acceptance date: 29/04/2014
ISSN (print): 1549-9634
ISSN (electronic): 1549-9642
Publisher: Elsevier Inc.
PubMed id: 24832960
Altmetrics provided by Altmetric